Project Grant R01CA289259
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$884K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $788,589 Project Grant (CFDA 93.398 Cancer Research Manpower) to Children's Hospital Los Angeles (CHLA) on August 15, 2024. The grant supports research to understand how the transcription factor FOXR2 cooperates with ETS transcription factors to drive the formation of diffuse midline gliomas, a devastating type of childhood brain tumor. The research aims to elucidate the role of MAPK signaling in FOXR2-expressing gliomas and test if ETS transcription...
This federal Project Grant award of $459,000 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to gain crucial insights into the biology of choroid plexus carcinoma (CPC), a rare and aggressive form of brain cancer primarily affecting young children. The project aims to examine the role of microRNAs in regulating the multiciliation program during choroid plexus development and tumorigenesis, with a focus on understanding the molecular mechanisms...
The National Cancer Institute (NCI) awarded a $531,550 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Texas State University to conduct research on discovering novel druggable targets for neuroblastoma differentiation therapy. The research aims to systematically investigate the human druggable genome to identify differentiation-blocking oncogenes in neuroblastoma cells, validate their functions, and evaluate differentiation-inducing activities of inhibitors...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The $172,193 grant, awarded on May 7, 2025, supports a 5-year research project to characterize gene regulatory elements and metabolic functions in a rare and aggressive form of renal cell carcinoma known as translocation renal cell carcinoma (TRCC). The research aims to develop optimization methods to...
The National Cancer Institute (NCI) awarded a $477,576 Project Grant (CFDA 93.396 Cancer Biology Research) to George Washington University to advance the understanding of the novel function of the SIRT1 enzyme and its implications in cancer, particularly medulloblastoma. The 5-year project aims to define the molecular mechanisms by which SIRT1 regulates centrosomal and ciliary biogenesis, and explore the therapeutic potential of manipulating SIRT1 activity to repress the growth of sonic hedgehog...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
This Project Grant award of $404,972 from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) supports research by the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate ribosome biogenesis and specialized translation in glioblastoma, the most aggressive form of brain cancer. The key objectives are to: 1) Identify differences in small nucleolar RNA (snoRNA) expression and rRNA modifications between glioma stem cells, astrocytes,...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) worth $718,113 to St. Jude Children's Research Hospital Inc. on January 15, 2025. The grant supports research aimed at understanding the mechanisms by which the MYC oncogenes interact with core regulatory circuitry transcription factors (CRC TFs) and epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), to promote neuroblastoma...
This federal Cooperative Agreement award, funded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to develop the first genetically engineered mouse model of desmoplastic small round cell tumor (DSRCT) and define its pathobiology. The $527,904 award, which runs from September 1, 2024 to August 31, 2029, aims to: 1) establish a DSRCT mouse model by inducing the EWSR1-WT1 gene fusion and studying the effects of...
The National Cancer Institute (NCI) awarded a $456,414 Project Grant under CFDA 93.395 - Cancer Treatment Research to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to conduct a phase 2 clinical trial of B7-H3 chimeric antigen receptor (CAR) T-cell therapy for children and young adults with diffuse intrinsic pontine glioma (DIPG), a fatal central nervous system tumor. The award will support the delivery of repeatedly dosed, locoregional B7-H3 CAR T cells at...